Neuron23
Neuron23 is a clinical-stage precision-medicine biotechnology company developing genetically targeted small-molecule therapies for neurological and immunological diseases, with a lead precision-medicine program focused on Parkinson's disease. It combines machine-learning-driven genetic biomarker discovery with drug development to match patients to the therapies most likely to help them. Surfaced in the API Evangelist network as a portfolio company of SoftBank Vision Fund, Neuron23 is a therapeutics company that publishes no public API, developer portal, SDK, or technical documentation surface as of this enrichment pass.
Neuron23 is profiled on the APIs.io network. Tagged areas include Company, Health Tech, Biotechnology, Precision Medicine, and Neuroscience.
Neuron23’s developer surface includes product news and 3 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 3
The organization behind the API